lurtotecan

NX-211 is the low-clearance liposomal formulation; structure in first source

Also Known As:

7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin; GG-211; GG211; GI 147211; GI-147211; GI147211; Gl 147211C; Gl-147211C; Gl147211C; NX 211; NX-211; NX211 cpd; OSI 211; OSI-211; OSI211

Networked: 21 relevant articles (3 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Camptothecin: 2033
    - lurtotecan: 21

Experts

1.	Barrett, Emma: 3 articles (03/2005 - 04/2004)
2.	Hamilton, Marta: 3 articles (03/2005 - 03/2002)
3.	Hamilton, M: 3 articles (08/2004 - 07/2000)
4.	Ptaszynski, M: 3 articles (08/2004 - 03/2001)
5.	Cameron, Terri: 2 articles (03/2005 - 03/2002)
6.	Eisenhauer, E: 2 articles (08/2004 - 04/2004)
7.	Fisher, B: 2 articles (08/2004 - 04/2004)
8.	Gelmon, K: 2 articles (08/2004 - 04/2004)
9.	Giles, Francis J: 2 articles (04/2004 - 11/2003)
10.	Desjardins, J P: 2 articles (03/2001 - 07/2000)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2001 - "These studies demonstrated that KB tumors of [14C]NX211-treated mice had approximately 70-fold greater concentrations of [14C]lurtotecan at 24 h, respectively, compared to concentrations of [14C]lurtotecan of the KB tumors of [14C]lurtotecan-treated mice. " 07/01/2000 - "GI147211, at the dose and schedule employed in this study, showed an acceptable safety profile but a modest antitumor activity in the examined tumor types." 03/01/2001 - "These findings are one of the keys justifying the development of a liposomal formulation of lurtotecan, which has the intent to increase tumor exposure and increase antitumor efficacy." 03/01/2001 - "HPLC analysis of extracted material from tumors of [14C]NX211-treated mice showed that more than 95% of the radioactive material was intact [14C]lurtotecan. " 03/01/2001 - "The area under curve (AUC) from 0 to 48 h of [14C]lurtotecan for the KB tumors of [14C]NX211-treated animals was over 17-fold greater than the AUC of [14C]lurtotecan for the tumors of [14C]lurtotecan-treated animals. "
2.	Ovarian Neoplasms (Ovarian Cancer) 03/20/2005 - "We studied two schedules of OSI-211 in a randomized design in relapsed ovarian cancer to identify the more promising of the two schedules for further study. " 04/01/2004 - "A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer." 04/01/2004 - "To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with topotecan resistant ovarian cancer. "
3.	Hematologic Neoplasms (Hematological Malignancy) 04/01/2004 - "OSI-211 merits further study in hematologic malignancies." 11/01/2003 - "In comparison to OSI-211, treatment with DaunoXome, the liposomal formulation of daunorubicin, a drug with clinical efficacy in AML and ALL, had no effect on survival in the KBM-3B, nor Molt-4 A4 leukemia models when administered at its maximum or near maximum tolerated doses of 3mg/kg d1, 8. These data demonstrate that OSI-211 has potent antileukemia activity in preclinical SCID mouse AML and ALL leukemia models, supporting the clinical investigation of OSI-211 for hematological malignancies."
4.	Thrombocytopenia (Thrombopenia) 03/01/2002 - "The dose-limiting toxicities of NX 211 are neutropenia and thrombocytopenia. " 03/01/1996 - "GI147211 is a new topoisomerase I inhibitor that induced dose-limiting neutropenia and thrombocytopenia in this phase I study. "
5.	Neutropenia 03/01/2002 - "The dose-limiting toxicities of NX 211 are neutropenia and thrombocytopenia. " 03/01/1996 - "GI147211 is a new topoisomerase I inhibitor that induced dose-limiting neutropenia and thrombocytopenia in this phase I study. "

Related Drugs and Biologics

1.	lurtotecan
2.	Topoisomerase I Inhibitors
3.	Topotecan (Hycamtin)
4.	9-aminocamptothecin
5.	Camptothecin
6.	Enzymes
7.	Type I DNA Topoisomerases (Topoisomerase I)
8.	Cisplatin (Platino)
9.	Trifluoroacetic Acid (Trifluoroacetate)
10.	Phosphatidylcholines (Phosphatidylcholine)

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Radiotherapy
3.	Therapeutics